期刊文献+

MDMX对非小细胞肺癌放疗抵抗性的研究进展 被引量:5

Progress of MDMX in the treatment of non-small cell lung cancer with radiotherapy resistance
下载PDF
导出
摘要 肺癌是目前全球范围内最常见的恶性肿瘤之一,发病率和死亡率居各肿瘤之首。近年来,随着医疗技术的不断发展,放疗作为肺癌一种非常重要的治疗方法 ,其抵抗性的研究越来越受到关注。目前,国内外关于MDMX(Murine double minute X,又称为MDM4)对非小细胞肺癌放疗抵抗性的研究较少。本文总结近年来肺癌领域与MDMX相关的放疗抵抗机制的研究,就MDMX与非小细胞肺癌放疗抵抗性的研究进展进行综述。 Lung cancer is one of the most common malignant tumors in the world,which morbidity and mortality are highest in all tumors.In recent years,with the continuous development of medical technology,radiotherapy as one of the most important treatment methods,the research on its resistivity has been paid more and more attention.So far,the research about the radiotherapy resistance of MDMX(murine double minute X,also known as MDM4) for non-small cell lung cancer is relatively rare at home and abroad.This paper summarizes the recent research related the mechanism of radiotherapy resistance of MDMX in the field of lung cancer and reviews the current progress of radiotherapy resistance of MDMX for non-small cell lung cancer.
作者 赵涵 黄伟 解玉卓 曾越灿 ZHAO Han;HUANG Wei;XIE Yu-zhuo;ZENG Yue-can(Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang 110022, China)
出处 《实用药物与临床》 CAS 2018年第3期330-332,共3页 Practical Pharmacy and Clinical Remedies
基金 国家自然科学基金(81201803) 辽宁省高等学校基本科研项目(LQNK201714)
关键词 MDMX 放疗抵抗性 肺癌 MDMX Radiotherapy resistance Lung cancer
  • 相关文献

参考文献2

二级参考文献30

  • 1王颖轶,陈书长.肿瘤标志物对晚期非小细胞肺癌患者放疗疗效的评估价值[J].实用癌症杂志,2014,29(1):23-25. 被引量:12
  • 2Shimada Y, Saji H, Yoshida K, et al. Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer [ J ]. Chest, 2013,143 (6) : 1626-1634. DOI, 10. 1378/chest. 12-1717.
  • 3Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance peme- trexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase3 study[J]. Lancet, 2009,374(9699):1432-1440. DOI: 10. 1016/S0140-6736 (09) 61497-5.
  • 4Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in pre- viously treated non-small-cell lung cancer (INTEREST) : a ran- domised phase Ⅲ trial[J]. Lancet, 2008,372 (9652) : 1809- 1818. DOI: 10. 1016/S0140-6736(08)61758-4.
  • 5Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-ceU lung cancer harbouring EGFR mutations (LUX-hmg 6 ): an open-label, randomised phase 3 trial [ J ]. Lancet Oncol, 2014, 15(2) :213-222. DOI: 10. 1016/S1470-2045(13)70604-1.
  • 6Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy[ J ]. FEBS J, 2010, 277(2) :309-315. DOI: 10. 1111/j. 1742-4658. 2009. 07449. x.
  • 7Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase Ⅲ, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) [J]. J Clin Oncol, 2011,29(21 ) : 2866- 2874. DOI: 10. 1200/JCO. 2010.33.4235.
  • 8孟凡亮,张德建,朱洪斌.CEA CYFRA21-1 NSE在肺癌化疗中的临床应用[J].安徽医学,2010,31(1):27-29. 被引量:7
  • 9朱景倩,朱丹,陈慧,骆健峰,盛琳.血清肿瘤标志物检测在肺癌诊断中的临床价值[J].中国卫生检验杂志,2010,20(1):141-143. 被引量:15
  • 10代忠,曹军,赵红艳.长春瑞滨联合顺铂治疗非小细胞肺癌临床观察[J].中国医药,2010,5(11):1016-1017. 被引量:5

共引文献31

同被引文献61

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部